Tetra Discovery Partners LLC is a leader is the chemical design of inhibitors of phosphodiesterase (PDE) enzymes. In the brain, PDEs are involved in cognition/memory, schizophrenia, depression and neuroinflammation. Tetra uses a structure-guided drug design chemistry approach to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4) subtypes such as PDE4B and PDE4D.
Tetra is targeting the function of PDE4s, to enhance memory formation in brain neurons, nerve dendrites involved in schizophrenia and depression, and brain microglia involved in brain inflammation. Tetra’s drug discovery platform can also be used to develop novel treatments for peripheral diseases where PDEs are attractive drug targets.
Latest NewsOctober 16, 2014
Tetra announces additional financing. Read this articleApril 9, 2014
Tetra announces collaboration with the Broad Institute to develop drug for schizophrenia. Read this articleJanuary 22, 2014
Tetra high school intern is semifinalist in the 2014 Intel Science Talent Search. Read this articleSeptember 30, 2013
Tetra completes $1 million seed financing led by Grand Angels. Read this article
- ASENT 17th Annual Meeting on February 19, 2015